SVA - Sinovac Biotech Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.47
0.00 (0.00%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close6.47
Open6.49
Bid0.00 x 800
Ask0.00 x 1100
Day's Range6.28 - 6.58
52 Week Range5.73 - 8.66
Volume0
Avg. Volume7,324
Market Cap640.001M
Beta (3Y Monthly)0.16
PE Ratio (TTM)12.94
EPS (TTM)0.50
Earnings DateJun 1, 2017 - Jun 5, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Trade prices are not sourced from all markets
  • Business Wire16 days ago

    Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares

    Sinovac Biotech Ltd. , a leading provider of biopharmaceutical products in China, today issued an update on the Exchange of Rights for Common and Series B Preferred Shares announced February 22, 2019.

  • Business Wirelast month

    Sinovac Determines Trigger Event Occurred Under Rights Agreement

    Board of Directors Amends and Restates Rights Agreement and Declares Dividend Distribution of New Preferred Share Purchase Rights. Sinovac Biotech Ltd. (SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that its Board of Directors (the “Board”) determined that certain stockholders became “Acquiring Persons,” as defined in the Company’s Rights Agreement (“Rights Agreement”), prior to the Company’s Annual General Meeting held on February 6, 2018 (the “AGM”).

  • Reuterslast month

    Sinovac Biotech activates 'poison pill' defense in rare move

    Sinovac Biotech Ltd, a Nasdaq-listed Chinese vaccine developer, activated a shareholders rights plan on Friday, according to a press release seen by Reuters, the first time a company has used a "poison pill" takeover defense in more than a decade. Sinovac is seeking to defend itself against a group of shareholders, including investment firms 1Globe Capital LLC, Chiangjia Li and OrbiMed Advisors LLC, which own 40 percent of the company. While companies occasionally threaten to use poison pill defenses, they rarely proceed.

  • GlobeNewswirelast month

    Nasdaq Halts Sinovac Biotech Ltd.

    NEW YORK, Feb. 22, 2019 -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading was halted today in Sinovac Biotech Ltd. (Nasdaq: SVA) at 16:02:01 p.m. Eastern Time.

  • Can Sinovac Biotech Ltd.’s (NASDAQ:SVA) ROE Continue To Surpass The Industry Average?
    Simply Wall St.3 months ago

    Can Sinovac Biotech Ltd.’s (NASDAQ:SVA) ROE Continue To Surpass The Industry Average?

    Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Read More...

  • Business Wire3 months ago

    Sinovac Comments on Antigua and Barbuda Court Decision Denying 1Globe Capital’s Claim; Current Board Was Validly Elected at Annual General Meeting

    Sinovac Biotech Ltd. (SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the High Court of Justice of Antigua and Barbuda rejected the claim of 1Globe Capital LLC (“1Globe”) for a declaration that an alternative slate of directors had been elected at the Company’s Annual General Meeting in February 2018. The Court’s decision means that the current directors of the Company were validly elected at the Annual General Meeting held in February 2018 (“AGM”) and remain the directors of the Company.

  • Business Wire3 months ago

    Haidian District People’s Court in Beijing Issues Injunction Order Restraining Aihua Pan from Using Business License and Corporate Seal of Sinovac Beijing

    Sinovac Biotech Ltd. (“Sinovac” or the “Company”) announced that the People’s Court in Haidian District, Beijing (the “Court”), has issued an interim injunction order restraining Mr. Aihua Pan from using or authorizing others to use the business license, corporate seal (No.:1101081347485), contract seal and invoice seal of the Company’s subsidiary, Sinovac Biotech Co., Ltd (“Sinovac Beijing”), that were improperly obtained by him.

  • Reuters4 months ago

    BRIEF-Hong Kong High Court Issues Declaratory Orders & Permanent Injunctive Relief In Favor Of Sinovac's Senior Management

    Nov 28 (Reuters) - Sinovac Biotech Ltd: * HONG KONG HIGH COURT ISSUES DECLARATORY ORDERS AND PERMANENT INJUNCTIVE RELIEF IN FAVOR OF SINOVAC’S BIOTECH LTD. SENIOR MANAGEMENT * SINOVAC BIOTECH - PERMANENT ...

  • Business Wire4 months ago

    Hong Kong High Court Issues Declaratory Orders and Permanent Injunctive Relief in Favor of Sinovac’s Biotech Ltd. Senior Management

    Senior management of Sinovac Biotech Ltd. (SVA) ("Sinovac" or the "Company") and the lawful directors of Sinovac Hong Kong, Mr. Yin Weidong and Ms. Wang Nan (“Lawful Directors”), have been granted declaratory orders and permanent injunctive relief against Mr. Li Pengfei (“Mr. Li”) and Mr. Cao Jianzeng (“Mr. Cao”) by the High Court of the Hong Kong Special Administrative Region (“Hong Kong High Court”). Mr. Li and Mr. Cao have appealed the decision to the Court of Appeals.

  • PR Newswire4 months ago

    Sinovac Reports Unaudited First Half of 2018 Financial Results

    BEIJING , Nov. 8, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China , announced today its ...

  • Business Wire5 months ago

    Sinovac Granted Interim Injunctive Relief Regarding Filings Bearing a Falsified Company Seal and Forged Board Member Signatures

    Senior management of Sinovac Biotech Ltd. (SVA) ("Sinovac" or the "Company") and the lawful directors of Sinovac Hong Kong (“Lawful Directors”), Mr. Yin Weidong and Ms. Wang Nan, have been granted interim injunctive relief against Mr. Li Pengfei (“Mr. Li”) and Mr. Cao Jianzeng (“Mr. Cao”) by the High Court of the Hong Kong Special Administrative Region (“Hong Kong High Court”). The interim injunction was granted in the Hong Kong High Court proceedings brought by the Lawful Directors to nullify and remove forged documents that were illegally filed with the Hong Kong Companies Registry (“Companies Registry”) in respect of Sinovac Biotech (Hong Kong) Limited (“Sinovac HK”).

  • PR Newswire5 months ago

    U.S. District Court in Massachusetts Denies 1Globe's Motion for Preliminary Injunction to Enjoin Sinovac's Issuance of Shares

    BEIJING , Oct. 17, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ:  SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China , today announced ...

  • Reuters5 months ago

    BRIEF-Sinovac Biotech Says Commences Legal Proceedings To Nullify Filings Bearing A Falsified Company Seal And Forged Board Member Signatures

    Oct 15 (Reuters) - Sinovac Biotech Ltd: * SINOVAC COMMENCES LEGAL PROCEEDINGS TO NULLIFY FILINGS BEARING A FALSIFIED COMPANY SEAL AND FORGED BOARD MEMBER SIGNATURES * SINOVAC BIOTECH-ALSO PETITIONED IN ...

  • Business Wire5 months ago

    Sinovac Commences Legal Proceedings to Nullify Filings Bearing a Falsified Company Seal and Forged Board Member Signatures

    Senior management of Sinovac Biotech Ltd. (SVA) ("Sinovac" or the "Company") and the lawful directors of Sinovac Hong Kong have commenced legal proceedings in the High Court of the Hong Kong Special Administrative Region to nullify and remove forged documents that were illegally filed with the Hong Kong Companies Registry in respect of Sinovac Biotech (Hong Kong) Limited (“Sinovac HK”) and with the Industry and Commerce Bureau of Beijing in respect of Sinovac Biotech Co., Ltd. (“Sinovac Beijing”). In addition, in the High Court of Justice in Antigua and Barbuda, the Company has petitioned for 1Globe Capital LLC (“1Globe”) to be restrained from making any attempt to take control of the company or in any other way undermine the court’s authority in the existing litigation between 1Globe and the Company.

  • Reuters5 months ago

    BRIEF-Sinovac Biotech Says Unauthorized Changes Have Been Made To The Hong Kong Companies Registry

    Oct 10 (Reuters) - Sinovac Biotech Ltd: * BECAME AWARE ON OCTOBER 8 THAT UNAUTHORIZED CHANGES HAVE BEEN MADE TO THE HONG KONG COMPANIES REGISTRY FOR SINOVAC BIOTECH LIMITED * UNAUTHORIZED CHANGES HAVE ...

  • Business Wire5 months ago

    Sinovac Comments on Unauthorized Use of Falsified Sinovac Hong Kong’s Company Seal and Subsidiary Board Member Signatures

    Sinovac Biotech Ltd. (SVA) ("Sinovac" or the "Company"), became aware Monday October 8, 2018 that unauthorized changes have been made to the Hong Kong Companies Registry for Sinovac Biotech (Hong Kong) Limited (“Sinovac HK”) and that unauthorized changes have been made to the Industry and Commerce Bureau of Beijing for Sinovac Biotech Co., Ltd. (“Sinovac Beijing”).

  • PR Newswire6 months ago

    DOJ Closes Investigation of Sinovac

    BEIJING , Sept. 17, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China , today announced ...

  • Benzinga7 months ago

    The Daily Biotech Pulse: Merck's Keytruda Secures Approval For Expanded Label, ProPhase Labs Q2 Loss Narrows

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 20) Avanos Medical Inc (NYSE: AVNS ) Becton Dickinson and Co (NYSE: ...

  • PR Newswire7 months ago

    SEC Concludes Investigation of Sinovac

    BEIJING , Aug. 20, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China , today announced ...

  • PR Newswire9 months ago

    Sinovac Raises $86.73 Million Through Private Placement Transaction

    BEIJING, July 3, 2018 /PRNewswire/ --Sinovac Biotech Ltd. (SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it has completed a private placement of its common shares (a "private investment in public equity," or "PIPE") with private investors Vivo Capital and Advantech Capital. Sinovac will receive gross proceeds of $86.73 million. The proceeds will be used to increase the Company's capabilities in research relating to quality control and to build additional production facilities to support the development and commercialization of sIPV-based combination vaccine and other new vaccine projects.

  • PR Newswire9 months ago

    Sinovac Files Motion for Summary Judgment on Rights Agreement in Delaware Chancery Court

    BEIJING, June 26, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it has filed a motion for partial summary judgment in Delaware Chancery Court. The motion introduces recently obtained information showing that the Sinobioway Consortium, led by Sinobioway Biomedicine Co., Ltd. ("Sinobioway"), a minority shareholder of the Company's controlled Chinese subsidiary, Sinovac Biotech Co., Ltd. ("Sinovac Beijing"), and a group of Sinovac's shareholders led by 1Globe and OrbiMed (the "Dissident Shareholders") reached an agreement, arrangement or understanding before the Company's annual general meeting held on February 6, 2018 (the "AGM"). Prior to the AGM, the Sinobioway Consortium and the Dissident Shareholders agreed to appear at the AGM to nominate and to vote for new directors controlled by Sinobioway or the Dissident Shareholders.

  • Is Sinovac Biotech Ltd’s (NASDAQ:SVA) PE Ratio A Signal To Buy For Investors?
    Simply Wall St.9 months ago

    Is Sinovac Biotech Ltd’s (NASDAQ:SVA) PE Ratio A Signal To Buy For Investors?

    Sinovac Biotech Ltd (NASDAQ:SVA) trades with a trailing P/E of 18.8x, which is lower than the industry average of 27.5x. While this makes SVA appear like a great stock toRead More...

  • PR Newswire9 months ago

    Sinovac Biotech Relaunches Company Website

    BEIJING , June 11, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ:  SVA ) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced ...

  • PR Newswire10 months ago

    Sinovac Files 2017 Annual Report on Form 20-F and Reports Unaudited Second Half, Audited Full Year 2017 Financial Results

    BEIJING , May 11, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China , announced today that ...

  • PR Newswire11 months ago

    Sinovac Forced to Temporarily Suspend Hepatitis A Vaccine Production Line Due to Disruptive Actions taken by Minority Shareholder of Sinovac Beijing

    BEIJING, May 8, 2018 /PRNewswire/ --  Sinovac Biotech Ltd. (SVA) ("Sinovac " or the "Company"), a leading provider of biopharmaceutical products in China, today announced it has been forced to suspend production at its plant for hepatitis A vaccine, and to destroy the bulk of its hepatitis A vaccines being produced at its Shangdi site, which is capable of producing approximately 3.5 million doses of finished product hepatitis A vaccines. The Company is not presently able to assess the impact on its sales of hepatitis A vaccine due to a lack of certainty regarding both the market's reaction to this incident, as well as the schedule for resuming production. Sinovac made this decision due to actions taken by Aihua Pan, the Chairman of the Board of the Company's controlled Chinese subsidiary, Sinovac Biotech Co., Ltd. ("Sinovac Beijing"), who was appointed by Sinobioway Biomedicine Co., Ltd. ("Sinobioway"), the minority shareholder of Sinovac Beijing.